Company news
Royalty Pharma plc news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Royalty Pharma Highlights Accomplishments and Provides Business Update at 40th Annual J.P. Morgan Healthcare Conference
January 9, 2022
Royalty Pharma and Cytokinetics Announce Funding Agreements Totaling up to $450 Million
January 6, 2022
Cytokinetics and Royalty Pharma Announce Funding Agreements Totaling up to $450 Million
January 6, 2022
Royalty Pharma Announces 12% Dividend Increase
January 5, 2022
Royalty Pharma to Present at the J.P. Morgan Healthcare Conference on January 10
January 4, 2022
Royalty Pharma to Present at Evercore ISI 4th Annual HealthCONx Virtual Conference
November 28, 2021
Royalty Pharma Acquires Additional Royalty Interests in BCX9930 and ORLADEYO from BioCryst Pharmaceuticals
November 21, 2021
Royalty Pharma Reports Third Quarter 2021 Results
November 9, 2021
Royalty Pharma to Announce Third-Quarter 2021 Financial Results on November 10, 2021
October 17, 2021
Royalty Pharma Declares Fourth-Quarter 2021 Dividend
October 14, 2021
Avillion announces positive results in MANDALA and DENALI Phase III trials of AstraZeneca's PT027, a fixed-dose combination of albuterol and budesonide, demonstrating significant benefits for asthma patients
September 8, 2021
Royalty Pharma Reports Second Quarter 2021 Results
August 10, 2021
Royalty Pharma to Announce Second-Quarter 2021 Financial Results on August 11, 2021
July 18, 2021
Royalty Pharma Declares Third-Quarter 2021 Dividend
July 15, 2021
Royalty Pharma Announces Pricing of $1.3 Billion of Senior Unsecured Notes, Including $600 Million Social Bond
July 14, 2021
Royalty Pharma Announces $2.025 Billion Strategic Funding Partnership With MorphoSys
June 1, 2021
Royalty Pharma Reports First Quarter 2021 Results
May 10, 2021
Royalty Pharma to Announce First-Quarter 2021 Financial Results on May 11, 2021
April 20, 2021
Royalty Pharma Announces Strategic Alliance With MSCI to Launch Life Sciences Indexes
April 20, 2021
Royalty Pharma Declares Second-Quarter 2021 Dividend
April 14, 2021
Royalty Pharma Acquires OXLUMO™ Royalty Interest From Dicerna for up to $240 Million
April 7, 2021
Dicerna Sells OXLUMO™ (lumasiran) Royalty Interest to Royalty Pharma for Up to $240 Million
April 7, 2021
Royalty Pharma Acquires Royalty Interest in Cabozantinib From GSK
March 31, 2021
Royalty Pharma Appoints Henry A. Fernandez as Lead Independent Director
March 29, 2021
Royalty Pharma Reports Q4 2020 and Full-Year Results
February 16, 2021
Royalty Pharma to Announce Fourth-Quarter 2020 Financial Results on February 17, 2021
January 21, 2021
Royalty Pharma Acquires Royalty Interest in Seltorexant From Minerva Neurosciences
January 18, 2021
Minerva Neurosciences and Royalty Pharma Announce Sale of Seltorexant Royalty for up to $155 Million
January 18, 2021
Royalty Pharma Announces 13% Dividend Increase
January 7, 2021
Royalty Pharma to Present at the J.P. Morgan Healthcare Conference on January 12
January 6, 2021
Royalty Pharma Announces Charitable Gifts to Support COVID-19 Research at Leading Hospitals and Universities
December 21, 2020
Royalty Pharma Acquires Royalty Interest in ORLADEYO and BCX9930 From BioCryst Pharmaceuticals
December 6, 2020
Royalty Pharma Reports Third Quarter 2020 Results
November 9, 2020
Royalty Pharma Acquires Additional Royalty Interest From the Cystic Fibrosis Foundation
November 1, 2020
Royalty Pharma Announces Closing of Secondary Offering of Class A Ordinary Shares by Selling Shareholders
October 19, 2020
Royalty Pharma to Announce Third-Quarter 2020 Financial Results on November 11, 2020
October 18, 2020
Royalty Pharma Declares Fourth-Quarter 2020 Dividend
October 14, 2020
Royalty Pharma Announces Secondary Offering of Class A Ordinary Shares by Selling Shareholders
October 12, 2020
Royalty Pharma Declares Third-Quarter 2020 Dividend
September 1, 2020
Royalty Pharma Announces Closing of $6.0 Billion Senior Unsecured Notes
September 1, 2020
Royalty Pharma Announces Pricing of $6.0 Billion Senior Unsecured Notes
August 24, 2020
Royalty Pharma Announces Launch of Senior Notes Offering
August 18, 2020
Royalty Pharma Reports Second Quarter 2020 Results
August 11, 2020
Biohaven and Royalty Pharma Announce Funding Agreement Totaling up to $450 Million
August 6, 2020
Royalty Pharma Appoints Henry A. Fernandez and Ted W. Love, M.D. to the Company’s Board of Directors
August 2, 2020
Royalty Pharma to Announce Second-Quarter 2020 Financial Results on August 12
July 19, 2020
Royalty Pharma Acquires Royalty Interest in Risdiplam From PTC Therapeutics
July 19, 2020
Calls
The 5 newest of 23 calls. Every call is listed under its year.
- Royalty Pharma (NASDAQ:RPRX) Q2 2026 Earnings Call
Aug 5, 2026
Transcript - Royalty Pharma (NASDAQ:RPRX) Q1 2026 Earnings Call
May 6, 2026
Transcript - Royalty Pharma (NASDAQ:RPRX) Q4 2025 Earnings Call
Feb 11, 2026
Transcript - Royalty Pharma (NASDAQ:RPRX) Q3 2025 Earnings Call
Nov 5, 2025
Transcript - Royalty Pharma (NASDAQ:RPRX) Q2 2025 Earnings Call
Aug 6, 2025
Transcript
Decks
The 5 newest of 60 decks. Every deck is listed under its year.
- Q2 2026 Earnings Presentation
Earnings · 33 slides · Aug 5, 2026
- Investor Presentation (August 2026)
Investor deck · 90 slides · August 2026
- Investor Presentation (August 2026)
Investor deck · 91 slides · August 2026
- Merger or Acquisition (August 2026)
Merger or acquisition · 7 slides · August 2026
- Investor Presentation (July 2026)
Investor deck · 7 slides · July 2026